- Home
- DERM vs GALT Comparison
DERM vs GALT Comparison
Compare DERM & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DERM
- GALT
- Stock Information
- Founded
- DERM 2014
- GALT 2000
- Country
- DERM United States
- GALT United States
- Employees
- DERM N/A
- GALT N/A
- Industry
- DERM Biotechnology: Pharmaceutical Preparations
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- DERM Health Care
- GALT Health Care
- Exchange
- DERM Nasdaq
- GALT Nasdaq
- Market Cap
- DERM 213.6M
- GALT 232.3M
- IPO Year
- DERM 2021
- GALT N/A
- Fundamental
- Price
- DERM $7.92
- GALT $6.25
- Analyst Decision
- DERM Strong Buy
- GALT Strong Buy
- Analyst Count
- DERM 3
- GALT 3
- Target Price
- DERM $12.67
- GALT $6.00
- AVG Volume (30 Days)
- DERM 256.5K
- GALT 432.8K
- Earning Date
- DERM 11-12-2025
- GALT 11-14-2025
- Dividend Yield
- DERM N/A
- GALT N/A
- EPS Growth
- DERM N/A
- GALT N/A
- EPS
- DERM N/A
- GALT N/A
- Revenue
- DERM $59,399,000.00
- GALT N/A
- Revenue This Year
- DERM $26.16
- GALT N/A
- Revenue Next Year
- DERM $45.27
- GALT N/A
- P/E Ratio
- DERM N/A
- GALT N/A
- Revenue Growth
- DERM 2.82
- GALT N/A
- 52 Week Low
- DERM $3.54
- GALT $0.73
- 52 Week High
- DERM $9.40
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- DERM 48.07
- GALT 66.51
- Support Level
- DERM $7.42
- GALT $5.10
- Resistance Level
- DERM $9.40
- GALT $6.15
- Average True Range (ATR)
- DERM 0.54
- GALT 0.55
- MACD
- DERM -0.14
- GALT 0.04
- Stochastic Oscillator
- DERM 27.53
- GALT 97.28
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.